How Mycobacterium tuberculosis Galactofuranosyl Transferase2 (GlfT2) Generates Alternating beta-(1-6) and beta-(1-5) Linkages: AQM/MM Molecular Dynamics Study of the Chemical Steps

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

JANOŠ Pavel KOZMON Stanislav TVAROŠKA Igor KOČA Jaroslav

Year of publication 2018
Type Article in Periodical
Magazine / Source Chemistry - A European Journal
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://doi.org/10.1002/chem.201800558
Doi http://dx.doi.org/10.1002/chem.201800558
Keywords enzyme catalysis; glycosyltransferases; molecular modeling; reaction mechanisms; tuberculosis
Description Mycobacterium tuberculosis features a unique cell wall that protects the bacterium from the external environment. Disruption of the cell wall assembly is a promising direction for novel anti-tuberculotic drugs. A key component of the cell wall is galactan, a polysaccharide chain composed of galactofuranose (Galf) units connected by alternating beta-(1–5) and beta-(1–6) linkages. The majority of the galactan chain is biosynthesized by a bifunctional enzyme—galactofuranosyl transferase 2 (GlfT2). GlfT2 catalyzes two reactions: the formation of beta-(1–5) and beta-(1–6) linkages. It was suggested that the enzyme acts through a processive mechanism until it adds 30–35 Galf units in a single active site. We applied a QM/MM string method coupled with ab initio molecular dynamics simulations to study the two reactions catalyzed by GlfT2. We showed that both reactions proceed very similarly and feature similar transition-state structures. We also present novel information about the ring puckering behavior of the five-membered furanose ring during the glycosyltransferase reaction and a calculated transition-state structure with galactose in a furanose form that may be used as a guide for the rational design of very specific and extremely potent inhibitors, that is, transition-state analogues, for GlfT2. Due to the absence of a furanose form of galactose in humans, transition-state-analogous inhibitors represent an attractive scaffold for the development of novel antibacterial drugs.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.